Mayo Clinic

Running trials

• Not yet recruiting

  Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial

  NCT06170281· Source

• Not yet recruiting

  Rimegepant For Endometriosis Pain

  NCT07795125· Phase 2· Source

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Source

• Recruiting

  A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

  NCT07359820· Phase 2· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Source

• Recruiting

  A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

  NCT07085104· Phase 1· Source

• Recruiting

  Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.

  NCT07048808· Phase 2· Source

• Recruiting

  Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients

  NCT07227961· Source

• Recruiting

  A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT06533644· Phase 2· Source

• Recruiting

  SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

  NCT06743126· Phase 3· Source

• Active, not recruiting

  A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

  NCT06607185· Phase 1· Source

• Active, not recruiting

  A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

  NCT06381141· Phase 1· Source

• Active, not recruiting

  A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

  NCT06285643· Phase 2· Source

• Recruiting

  A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

  NCT06395519· Phase 1/2· Source

• Active, not recruiting

  A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

  NCT05873686· Phase 1· Source

• Recruiting

  Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

  NCT05951179· Phase 2· Source

• Recruiting

  FOG-001 in Locally Advanced or Metastatic Solid Tumors

  NCT05919264· Phase 1/2· Source

• Recruiting

  Understanding of Genetics by Men at Risk for Prostate Cancer

  NCT04550845· Source

• Recruiting

  Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  NCT05519449· Phase 1· Source

• Recruiting

  Determining the Utility of a Behavioral Intervention in Chronic Migraine

  NCT05415020· Source

• Recruiting

  Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

  NCT05245500· Phase 1· Source

• Recruiting

  Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

  NCT05102019· Source

• Recruiting

  Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  NCT05051722· Source

• Recruiting

  DALY II USA/ MB-CART2019.1 for DLBCL

  NCT04792489· Phase 2· Source

• Recruiting

  Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  NCT04588922· Phase 1/2· Source

• Active, not recruiting

  Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

  NCT04756726· Phase 1· Source

• Active, not recruiting

  Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Phase 3· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

  NCT04906434· Phase 1· Source

• Recruiting

  A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  NCT03972657· Phase 1/2· Source

• Active, not recruiting

  9-ING-41 in Patients With Advanced Cancers

  NCT03678883· Phase 2· Source

• Active, not recruiting

  Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

  NCT03767348· Phase 2· Source

• Active, not recruiting

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Phase 2· Source

• Active, not recruiting

  A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

  NCT02912949· Phase 2· Source

• Active, not recruiting

  A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

  NCT02138734· Phase 1/2· Source

• Recruiting

  Blue Light Cystoscopy With Cysview® Registry

  NCT02660645· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer6 recruiting
• Endometrial cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Bladder cancer2 recruiting
• Colorectal cancer2 recruiting
• Coronary artery disease2 recruiting
• Gastric and esophageal cancer2 recruiting
• Migraine2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Sarcoma2 recruiting
• Acute myeloid leukemia1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometriosis1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

  NCT06604442· Phase 4· Source

• Terminated

  Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

  NCT05980416· Phase 1· Source

• Completed

  A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

  NCT05918692· Phase 1· Source

• Completed

  HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

  NCT05902494· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Source

• Completed

  A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

  NCT05360680· Phase 1· Source

• Completed

  Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

  NCT05243862· Phase 2· Source

• Terminated

  XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

  NCT05038644· Phase 1· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

  NCT04958785· Phase 2· Source

• Terminated

  EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

  NCT04892472· Phase 2· Source

• Completed

  Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

  NCT04484142· Phase 2· Source

• Terminated

  CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

  NCT04698187· Phase 2· Source

• Terminated

  A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

  NCT04432207· Phase 1· Source

• Recruiting

  Evaluate the Safety and Clinical Activity of HH2853

  NCT04390737· Phase 1/2· Source

• Completed

  REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

  NCT04526106· Phase 1/2· Source

• Terminated

  Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

  NCT04305444· Phase 2· Source

• Completed

  Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

  NCT03532295· Phase 2· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· Source

• Terminated

  Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure

  NCT03879629· Phase 2· Source

• Completed

  CardiAMP™ Cell Therapy for Heart Failure Trial

  NCT02438306· Phase 3· Source

• Completed

  A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

  NCT02932449· Source

• Completed

  Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

  NCT02576496· Phase 1· Source

• Terminated

  Study of rSIFN-co for Patients With Advanced Solid Tumors

  NCT02464007· Phase 1· Source